Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 91.84% | -690.51% | -547.12% | -372.13% | -1,091.42% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -95.59% | -73.80% | -79.19% | -85.53% | -1.75% |
| Total Other Non-Cash Items | -99.31% | 790.87% | 765.97% | 747.06% | 822.84% |
| Change in Net Operating Assets | 43.70% | 76.20% | 420.48% | 387.81% | 265.50% |
| Cash from Operations | 65.97% | 77.27% | 97.28% | -26.82% | 26.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -65.00% | -77.46% | -73.17% | 75.00% | 7.69% |
| Total Debt Repaid | 70.85% | 39.57% | 4.36% | -115.45% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -61.17% | -90.18% | -87.05% | 62.32% | -34.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.91% | -207.20% | 25.70% | 80.20% | -516.67% |
